ASH announces new executive committee members
Click Here to Manage Email Alerts
Three individuals have been elected to American Society of Hematology’s executive committee.
Mohandas Narla, DSc, will serve a 1-year term as vice president, followed by successive terms as president-elect and president.
Sarah H. O’Brien, MD, MSc, and Wendy Stock, MD, MA, each will serve 4-year terms as councillors.
Their terms will begin after this year’s ASH Annual Meeting, scheduled for Dec. 11-14 in Atlanta.
“Drs. Narla, O’Brien and Stock have been dedicated leaders within ASH and represent some of the brightest minds in the field of hematology,” ASH President Martin S. Tallman, MD, chief of the leukemia service at Memorial Sloan Kettering Cancer Center, said in a society-issued press release. “Under their leadership, the society will be well-positioned to be at the forefront of medical education and cutting-edge research, foster a strong and competitive workforce, and advocate on behalf of hematology patients worldwide.”
Narla, distinguished scientist at New York Blood Center, has made multiple contributions to research focused on the pathophysiology of inherited and acquired red blood cell disorders. His research interests include hereditary spherocytosis, sickle cell disease, thalassemias and malaria.
O’Brien is associate professor of pediatrics at The Ohio State University College of Medicine, and director of experimental therapeutics within the division of hematology/oncology/bone marrow transplant and principal investigator for Center for Child Health Equity and Outcomes Research at Abigail Wexner Research Institute at Nationwide Children’s Hospital. Her research interests include evaluation and diagnosis of mild bleeding disorders, thrombosis and thromboprophylaxis, as well as the relationship between hematology and women’s health.
Stock is professor of medicine and Anjuli Seth Nayak professor of leukemia research at The University of Chicago, as well as co-program leader of clinical and experimental therapeutics at The University of Chicago Comprehensive Cancer Center. Her research interests include translational and clinical studies for patients with acute lymphoblastic leukemia and acute myeloid leukemia, with a clinical focus on adolescent and young adult ALL.
Click Here to Manage Email Alerts